SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001104659-22-020374
Filing Date
2022-02-11
Accepted
2022-02-11 15:12:53
Documents
1
Group Members
FORESITE CAPITAL FUND IV, L.P.FORESITE CAPITAL FUND V, L.P.FORESITE CAPITAL MANAGEMENT III, LLCFORESITE CAPITAL MANAGEMENT IV, LLCFORESITE CAPITAL MANAGEMENT V, LLCJAMES TANANBAUM

Document Format Files

Seq Description Document Type Size
1 SC 13G/A tm225964d4_sc13ga.htm SC 13G/A 126769
  Complete submission text file 0001104659-22-020374.txt   128575
Mailing Address 640 LEE ROAD SUITE 200 WAYNE PA 19087
Business Address 640 LEE ROAD SUITE 200 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Subject) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-89137 | Film No.: 22620012
SIC: 2834 Pharmaceutical Preparations

Mailing Address 600 MONTGOMERY STREET SUITE 4500 SAN FRANCISCO CA 94111
Business Address 600 MONTGOMERY STREET SUITE 4500 SAN FRANCISCO CA 94111 415-877-4887
Foresite Capital Fund III, L.P. (Filed by) CIK: 0001645158 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A